Commentary

Low HPV Vaccination in the United States Is a Public Health ‘Failure’


 

This transcript has been edited for clarity.

I would like to briefly discuss what I consider to be a very discouraging report and one that I believe we as an oncology society and, quite frankly, as a medical community need to deal with.

The manuscript I’m referring to is from the United States Department of Health and Human Services, titled, “Human Papillomavirus Vaccination Coverage in Children Ages 9-17 Years: United States, 2022.” This particular analysis looked at the coverage of both men and women — young boys and young girls, I would say — receiving at least one dose of the recommended human papillomavirus (HPV) vaccination.

Since 2006, girls have been recommended to receive HPV vaccination; for boys, it’s been since 2011. Certainly, the time period that we’re considering falls within the recommendations based on overwhelmingly positive data. Now, today, still, the recommendation is for more than one vaccine. Obviously, there may be evidence in the future that a single vaccination may be acceptable or appropriate. But today, it’s more than one.

In this particular analysis, they were looking at just a single vaccination. The vaccines have targeted young individuals, both male and female children aged 11-12 years, but it’s certainly acceptable to look starting at age 9.

What is the bottom line? At least one dose of the HPV vaccination was given to 38.6% of children aged 9-17 years in 2022. We are talking about a cancer-preventive vaccine, which on the basis of population-based data in the United States, but also in other countries, is incredibly effective in preventing HPV-associated cancers. This not only includes cervical cancer, but also a large percentage of head and neck cancers.

For this vaccine, which is incredibly safe and incredibly effective, in this country, only 38.6% have received even a single dose. It is noted that the individuals with private insurance had a higher rate, at 41.5%, than individuals with no insurance, at only 20.7%.

In my opinion, this is clearly a failure of our public health establishment at all levels. My own focus has been in gynecologic cancers. I’ve seen young women with advanced cervical cancer, and this is a disease we can prevent. Yet, this is where we are.

For those of you who are interested in cancer prevention or public health, I think this is a very sobering statistic. It’s my plea and my hope that we can, as a society, somehow do something about it.

I thank you for listening. I would encourage you to think about this question if you’re in this area.

Dr. Markman, professor, Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, and president of Medicine & Science, City of Hope Atlanta, Chicago, and Phoenix, disclosed ties with GlaxoSmithKline and AstraZeneca.

A version of this article appeared on Medscape.com.

Recommended Reading

Effect of COVID-19 Vaccination on Disease Severity in Patients With Stable Plaque Psoriasis: A Cross-sectional Study
MDedge Dermatology
How clinicians can prepare for and defend against social media attacks
MDedge Dermatology
Global measles deaths increased by 43% in 2022
MDedge Dermatology
Shingles Vaccine Offers 4 Years of Protection
MDedge Dermatology
Coming Soon: The First mRNA Vaccine for Melanoma?
MDedge Dermatology
Reduced-Dose Vaccines Protect Patients With HIV Against Mpox
MDedge Dermatology
Measles Control So Far in 2024: ‘Not Off to a Great Start’
MDedge Dermatology
New mRNA Vaccines in Development for Cancer and Infections
MDedge Dermatology
Online Diagnosis of Sexually Transmitted Infections? Ethicist Says We Are Nowhere Close
MDedge Dermatology
Study Links Newer Shingles Vaccine to Delayed Dementia Diagnosis
MDedge Dermatology